ClinConnect ClinConnect Logo
Search / Trial NCT06355102

The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Apr 3, 2024

Trial Information

Current as of September 10, 2025

Enrolling by invitation

Keywords

Sudden Sensorineural Hearing Loss Tinnitus Chronicity Functional Magnetic Resonance Imaging Metabolomics

ClinConnect Summary

The incidence rate of tinnitus is very high globally and shows an increasing trend year by year. Sudden sensorineural hearing loss (SSNHL) , a prevalent otolaryngological emergency, often coincides with tinnitus among its patient population. This condition can significantly impact individuals' interpersonal relationships, work performance, and daily functioning, ultimately leading to a diminished quality of life and even psychological disturbances, such as anxiety and depression. Consequently, it is imperative to expore the mechanisms underlying the emergence and chronicity of tinnitus foll...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Group of SSNHL with Tinnitus:
  • 1. Age between 18 and 65 years old;
  • 2. Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
  • 3. Presence of tinnitus;
  • 4. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
  • 2. Group of SSNHL without Tinnitus:
  • 1. Age between 18 and 65 years old;
  • 2. Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
  • 3. Absence of tinnitus;
  • 4. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
  • 3. Healthy Control:
  • 1. Age between 18 and 65 years old;
  • 2. Normal hearing screening results;
  • 3. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
  • Exclusion Criteria:
  • 1. Previous diagnosis of otic organic diseases such as otitis media, cholesteatoma of the middle ear, Ménière's disease, acoustic neuroma, hereditary deafness, inner ear malformations, etc.; history of ear surgery; long-term exposure to noise; use of ototoxic drugs;
  • 2. Presence of brain organic diseases such as cerebral infarction, brain tumor, or contraindications for functional magnetic resonance imaging (fMRI) during nuclear magnetic resonance (NMR) examination;
  • 3. History of mental illness, including anxiety, depression, insomnia, etc.;
  • 4. Individuals unable to cooperate due to severe mental factors.

About The First Affiliated Hospital With Nanjing Medical University

The First Affiliated Hospital of Nanjing Medical University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to implementing rigorous scientific methodologies to evaluate new therapies and treatment approaches. With a multidisciplinary team of experienced healthcare professionals and researchers, the hospital fosters a collaborative environment aimed at enhancing patient outcomes and contributing to the global medical community. Its strategic focus on translational medicine ensures that groundbreaking discoveries are efficiently translated into practical applications for patient care.

Locations

Nanjing, Jiangsu, China

Patients applied

0 patients applied

Trial Officials

Liyuan Zhang, M.D.

Principal Investigator

Department of Otolaryngology, the First Affiliated Hospital, Nanjing Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported